Interleukin Genetics launches new version of Heart Health Test
This article was originally published in Clinica
Interleukin Genetics has launched its enhanced Heart Health Genetic Test in the US and Canada. It is an upgrade of the Gensona Heart Health Genetic Test, marketed by Quixtar/Amway, which was launched in 2006. Interleukin developed the diagnostic and licensed it to Quixtar, which prepares the test kit. Interleukin analyses the test and provides its report via its CLIA-registered laboratory. The Waltham, Massachusetts firm explained that the test itself was not new, but it now provides a comprehensive report, which includes quantified risk information on heart attack and coronary artery disease, and more complete information on a person's inflammation-based genetic risk factor for heart attack.